Laura Biganzoli

Hospital of Prato

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Angelo Di Leo

Hospital of Prato

136

Emanuela Risi

Hospital of Prato

Luca Malorni

Hospital of Prato

Chiara Biagioni

Hospital of Prato

Ilenia Migliaccio

Hospital of Prato

Amelia McCartney

Monash Health

Giuseppe Curigliano

European Institute of Oncology

Erica Moretti

Hospital of Prato

Matteo Benelli

Hospital of Prato

Martine Piccart

Université Libre de Bruxelles

Cooperative Institutions

Istituti di Ricovero e Cura a Carattere Scientifico

227

Dana-Farber Cancer Institute

126

Institut Jules Bordet

113

Hospital of Prato

106

International Breast Cancer Study Group

102

Memorial Sloan Kettering Cancer Center

102

European Institute of Oncology

100

Fondazione IRCCS Istituto Nazionale dei Tumori

University of Milan

Breast Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents

Current Breast Cancer Reports (2011)

Catherine Oakman Libero Santarpia Erica Moretti Laura Biganzoli Angelo Di Leo

Fulvestrant

Surgical oncology

Aromatase inhibitor

Estrogen receptor alpha

10.1007/s12609-010-0033-1

Cite

Citations (0)

Supplementary Figure 3 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Ian E. Krop Vandana G. Abramson Marco Colleoni Tiffany A. Traina Frankie A. Holmes

<p>Plasma trough concentrations by week for (A) enzalutamide and (B) exemestane The labeled values denote mean (SD). The open circles denote trough concentration values of individual patients. Solid squares and vertical lines denote mean with error bars by one SD in both directions. Abbreviations: SD, standard deviation.</p>

Exemestane

Enzalutamide

Trough (economics)

10.1158/1078-0432.22476930.v1

Cite

Citations (0)

What is the effect of systemic anticancer treatment on cognitive function?

The Lancet Oncology (2004)

Alessandro Marco Minisini Gül Atalay Andrew Bottomley Fabio Puglisi Martine Piccart

10.1016/s1470-2045(04)01465-2

Cite

Citations (97)

E12. Progress in systemic therapy for breast cancer

European Journal of Cancer (2002)

Martine Piccart Fátima Cardoso G. Atalay Laura Biganzoli

Systemic therapy

Source

Cite

Citations (0)

Breast Cancer

Oxford University Press eBooks (2008)

Fabio Efficace Laura Biganzoli

Abstract Breast cancer ranks first amongst cancers affecting women throughout the world. More than 1,050,000 new breast cancer cases occur worldwide annually, with nearly 580,000 occurring in developed countries. In most developed countries, 5-year survival rates are higher than 70 per cent. A greater percentage of patients are being diagnosed when curative approaches are still possible. However, approximately 10 per cent of newly diagnosed patients will present with metastatic disease and an additional 50–75 per cent will eventually relapse. The treatment for metastatic dis- ease, in spite of clinical responses to the various standard therapies (hormonal, chemotherapeutic, biological agents or their combination), is generally palliative and median survival is approximately 2 years.

Hormonal Therapy

10.1093/oso/9780198530220.003.0011

Cite

Citations (1)

Corrigendum to “About the French prohibition of textured breast implants: Is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position” [Breast 46 (August 2019) 95–96]

The Breast (2019)

Maria João Cardoso Laura Biganzoli Isabel T. Rubio Marjut Leidenius Giuseppe Curigliano

Position (finance)

Breast implant

10.1016/j.breast.2019.10.010

Cite

Citations (0)

The requirements of a specialist breast centre

The Breast (2020)

Laura Biganzoli Fátima Cardoso Marc Beishon David Cameron Luigi Cataliotti

This article is an update of the requirements of a specialist breast centre, produced by EUSOMA and endorsed by ECCO as part of Essential Requirements for Quality Cancer Care (ERQCC) programme, and ESMO.To meet aspirations for comprehensive cancer control, healthcare organisations must consider the requirements in this article, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis, to treatment, to survivorship.•The centrepiece of this article is the requirements section, comprising definitions; multidisciplinary structure; minimum case, procedure and staffing volumes; and detailed descriptions of the skills of, and resources needed by, members and specialisms in the multidisciplinary team in a breast centre.•These requirements are positioned within narrative on European breast cancer epidemiology, the standard of care, challenges to delivering this standard, and supporting evidence, to enable a broad audience to appreciate the importance of establishing these requirements in specialist breast centres.

Staffing

10.1016/j.breast.2020.02.003

Cite

Citations (147)

Cyclophosphamide (C) - Epirubicine (E) - Capecitabine (X) combination, CEX: A safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study

European Journal of Cancer (2001)

Laura Biganzoli Hervé Bonnefoi L. Mauriac Tanja Čufer E. Ngalula Kabanga

Regimen

10.1016/s0959-8049(01)81031-5

Cite

Citations (6)

8P Mutational analysis of circulating tumour DNA (ctDNA) in patients with ER+/HER2- advanced breast cancer (ABC) receiving palbociclib (P): Results from the TREnd trial

Annals of Oncology (2021)

Luca Malorni Dario Romagnoli Matteo Benelli Francesca Galardi Chiara Biagioni

Palbociclib

Progression-free survival

10.1016/j.annonc.2021.03.022

Cite

Citations (0)

Intermediate Bulk Containers Re-use in the Circular Economy: An LCA Evaluation

Procedia CIRP (2018)

Laura Biganzoli Lucia Rigamonti Mario Grosso

The transition towards a circular economy, where the value of products, materials and resources is maintained for as long as possible, is an essential contribution to the European Union's efforts to develop a sustainable economy. Re-use of packaging items plays a key role in the achievement of this goal. The aim of this study is to assess the environmental impacts associated to the life cycle of Intermediate Bulk Containers (IBCs) as the number of uses (the so-called "rotations") changes, by using the life cycle assessment (LCA) methodology. The results of the contribution analysis show that the impacts of the life cycle of IBCs mainly come from the IBCs manufacturing, whereas the reconditioning process accounts for less than 20% of the overall impacts. Moreover, the system where IBCs are reconditioned and re-used has better environmental performance than the system where IBCs are used only once and then sent to recycling/disposal. The advantages of such a system increase with the number of rotations.

Circular Economy

Product life-cycle management

10.1016/j.procir.2017.11.010

Cite

Citations (19)